CN Patent

CN110354125A — 一种治疗幽门螺杆菌感染的组合物及其制剂和用途

Assigned to Zhuhai Sailong Pharmaceutical Co Ltd · Expires 2019-10-22 · 7y expired

What this patent protects

本发明提供一种治疗幽门螺杆菌感染的组合物及其制剂和用途，该组合物包括重量份数比为10‑20：70‑120：2.2‑4的利福布丁、阿莫西林和左旋泮托拉唑钠；该组合物可将二线三联疗法治疗周期缩短20％，降低了患者治疗成本。本发明还提供一种用于治疗幽门螺杆菌感染的胶囊剂，该胶囊剂可以提高患者的依从性，进而提高对幽门螺杆菌的根除率。

USPTO Abstract

本发明提供一种治疗幽门螺杆菌感染的组合物及其制剂和用途，该组合物包括重量份数比为10‑20：70‑120：2.2‑4的利福布丁、阿莫西林和左旋泮托拉唑钠；该组合物可将二线三联疗法治疗周期缩短20％，降低了患者治疗成本。本发明还提供一种用于治疗幽门螺杆菌感染的胶囊剂，该胶囊剂可以提高患者的依从性，进而提高对幽门螺杆菌的根除率。

Drugs covered by this patent

Patent Metadata

Patent number
CN110354125A
Jurisdiction
CN
Classification
—
Expires
2019-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Zhuhai Sailong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.